PATENT CLAIM ANALYSIS

Application Number: 15743756
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-09
Patent Classification: ["530", "387300"]

Abstract:
The present disclosure relates to antibody molecules comprising a binding domain specific to CD22, said binding domain comprising SEQ ID NO: 1, 2, 3, 4, 5 and 6 or 7. The disclosure also extends to pharmaceutical compositions comprising said antibody molecules and use of the antibody molecules/compositions in treatment.

Claim (Index 47):
The antibody molecule of  claim 3 , wherein X 1  is F, X 3  is S, X 6  is W or Y, X 8  is S, X 12  is G, X 18  is S, X 33  is D, X 34  is A, X 35  is Q, X 36  is S, X 38  is S or Y, X 39  is S or N, X 41  is absent, X 42  is absent, X 43  is A, X 45  is A, X 46  is T, X 47  is A, X 48  is D, X 49  is D, X 52  is S or G, X 53  is Y, X 54  is Y, X 55  is S or Y, X 56  is S, X 60  is S or D, X 61  is W or Y, X 63  is absent, and X 64  is absent.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 1.46154
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15743764', '15326501', '15627161', '15430998', '13107439']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.779598526970358
- 35 USC 102 Novelty (BERT): 0.6047511241848216
- Combined Prediction Score: 0.7621137866918044
- Mean Citation Score: 451.072982
- Max Citation Score: 608.11847
- Similarity Product: 403.5978525918388

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test